title: [Sivelestat sodium hydrate was effective for ARDS in a patient suffering from chronic rheumatoid arthritis with acute exacerbation after failing to respond to high dose steroid pulse therapy].
abstract: Sivelestat sodium hydrate (ELASPOL) was effective for ARDS in a fifty-year-old female patient suffering from chronic rheumatoid arthritis with acute exacerbation, after failing to respond to high dose steroid pulse therapy. In ICU, the patient had bilateral lung opacities, especially of the upper lobes, respiratory acidosis, hypercapnea (PaCO2 89 mmHg), and poor oxygenation (P/F ratio 193). High dose steroid pulse therapy had been performed, but oxygenation was not improved, and a low level of oxygenation (P/F ratio 155) persisted. Sivelestat was started two days after finishing the steroid pulse therapy. The butterfly shadow on chest X ray and impaired oxygenation were markedly improved from the third day of sivelestat administration. Respiratory support was terminated with P/F ratio 300. Plasma concentrations of SP-A and SP-D decreased after sivelestat administration, but concentration of KL-6 was still elevated. In this case, sivelestat was effective for ARDS in the patient not responding to steroid pulse therapy, and clinical finding and plasma concentrations of SP-A and SP-D were correlated well.
authors.affiliation: Division of Intensive Care Medicine, Department of Anesthesiology, Faculty of Medicine, University of the Ryukyu, Okinawa 903-0215.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tomiyama
authors.forename: Itaru
authors.initials: I
authors.lastname: Takara
authors.forename: Joho
authors.initials: J
authors.lastname: Tokumine
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Sugahara
mesh_terms: D000941:Antigens / Q000097:blood; D000951:Antigens, Neoplasm; D001172:Arthritis, Rheumatoid / Q000150:complications*; D015415:Biomarkers / Q000097:blood; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D018396:Mucin-1; D009077:Mucins; D037662:Pulmonary Surfactant-Associated Protein A / Q000097:blood; D037663:Pulmonary Surfactant-Associated Protein D / Q000097:blood; D020551:Pulse Therapy, Drug; D012128:Respiratory Distress Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000941:Antigens; D000951:Antigens, Neoplasm; D015415:Biomarkers; D006023:Glycoproteins; C060192:MUC1 protein, human; D018396:Mucin-1; D009077:Mucins; D037662:Pulmonary Surfactant-Associated Protein A; D037663:Pulmonary Surfactant-Associated Protein D; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; C069195:sivelestat; D019272:Leukocyte Elastase; D005998:Glycine; D008775:Methylprednisolone